Climb Bio Inc (CLYM NASDAQ) stock market data APIs
$4.6844
-0.24(-5.1%)
as of February 2, 2026
Try our APIs with
free plan!
Climb Bio Inc Financial Data Overview
Price chart is built with
Anychart
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Prev. Close
4.6844
Open
4.4444
High
4.753
Low
4.4079
52 wk Range
1.05-5.3
Market Cap
305 M
Shares Outstanding
47 744 K
EPS
-0.19
Beta
-0.152
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Climb Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Climb Bio Inc data using free add-ons & libraries
Get Climb Bio Inc Fundamental Data
Climb Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.1467
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Climb Bio Inc News
New
Cheap high flyer healthcare stocks - high momentum and low valuation
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As earnings season ramps up and geopolitical tensions keep affecting the mark...
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks
Climb Bio Inc. (NASDAQ:CLYM) is one of the best biotech penny stocks to buy according to analysts. On December 18, H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb ...
Data-Rich Year Ahead - Will 2026 Readouts Lift Climb Bio Higher
(RTTNews) - For Climb Bio Inc. (CLYM), 2026 promises to be a data-rich year, with study results from two of its core programs poised to shape the company's strategy and guide subsequent development ph...
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
